Roche nabs first global approval for self-injected PNH treatment
08 Feb 2024
Drug ApprovalPhase 3Clinical Result
Roche’s crovalimab gained its first approval anywhere in the world with clearance in China for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). The authorisation, announced Thursday by partner Chugai, allows patients to administer the anti-C5 recycling monoclonal antibody at home by subcutaneous self-injection every four weeks.
The approval was based on results from a number of Phase III studies, including COMMODORE 3, which was conducted in China, and the global COMMODORE 2 trial. The therapy utilises Chugai’s recycling antibody technology, allowing crovalimab to bind to the C5 antigen repeatedly, enabling sustained complement inhibition at a low dose.
Regulatory applications for crovalimab are also under review in the US, Europe and Japan.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.